keyword
MENU ▼
Read by QxMD icon Read
search

ET-743

keyword
https://www.readbyqxmd.com/read/27615729/efficacy-of-trabectedin-for-the-treatment-of-liposarcoma
#1
Ritika Zijoo, Margaret von Mehren
INTRODUCTION: Trabectedin (ET-743) is a synthetic marine derived alkylating agent, extracted originally from a Caribbean Sea sponge. It is approved for the treatment of Soft Tissue sarcomas (STS) in Europe and recently by the FDA for liposarcomas and leiomyosarcomas. AREAS COVERED: Trabectedin has multiple mechanisms of action, including one targeting the FUS-CHOP oncogene in Myxoid/Round cell Liposarcomas. Numerous Phase I, II and III clinical trials have been conducted with Trabectedin...
October 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27077926/trabectedin-is-a-promising-antitumour-agent-for-synovial-sarcoma
#2
Hirohiko Yasui, Yoshinori Imura, Hidetatsu Outani, Ken-Ichiro Hamada, Takaaki Nakai, Shutaro Yamada, Satoshi Takenaka, Satoru Sasagawa, Nobuhito Araki, Kazuyuki Itoh, Akira Myoui, Hideki Yoshikawa, Norifumi Naka
Synovial sarcoma (SS) is an aggressive soft tissue tumour with poor prognosis. Using five human SS cell lines, we examined the cytotoxic effects of trabectedin (ET-743; Yondelis(®)), a novel marine natural product, which was approved in Europe for the treatment of soft tissue sarcomas (STS). The significant growth inhibitory effects were observed in all SS cell lines below nanomolar concentration of trabectedin. Furthermore, trabectedin significantly suppressed the tumour growth in xenograft models. Flow cytometer analysis in vitro and immunohistochemical analysis in vivo revealed its effect of cell cycle inhibition and apoptosis induction...
October 2016: Journal of Chemotherapy
https://www.readbyqxmd.com/read/27029031/dual-inhibition-of-atr-and-atm-potentiates-the-activity-of-trabectedin-and-lurbinectedin-by-perturbing-the-dna-damage-response-and-homologous-recombination-repair
#3
Michelle Lima, Hana Bouzid, Daniele G Soares, Frédéric Selle, Claire Morel, Carlos M Galmarini, João A P Henriques, Annette K Larsen, Alexandre E Escargueil
Trabectedin (Yondelis®, ecteinascidin-743, ET-743) is a marine-derived natural product approved for treatment of advanced soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer. Lurbinectedin is a novel anticancer agent structurally related to trabectedin. Both ecteinascidins generate DNA double-strand breaks that are processed through homologous recombination repair (HRR), thereby rendering HRR-deficient cells particularly sensitive. We here characterize the DNA damage response (DDR) to trabectedin and lurbinectedin in HeLa cells...
May 3, 2016: Oncotarget
https://www.readbyqxmd.com/read/26666647/unique-features-of-trabectedin-mechanism-of-action
#4
REVIEW
Annette K Larsen, Carlos M Galmarini, Maurizio D'Incalci
Trabectedin (Yondelis®, ET-743) is a marine-derived natural product that was initially isolated from the marine ascidian Ecteinascidia turbinata and is currently prepared synthetically. Trabectedin is used as a single agent for the treatment of patients with soft tissue sarcoma after failure of doxorubicin or ifosfamide or who are unsuited to receive these agents, and in patients with relapsed, platinum-sensitive ovarian cancer in combination with pegylated liposomal doxorubicin. Trabectedin presents a complex mechanism of action affecting key cell biology processes in tumor cells as well as in the tumor microenvironment...
April 2016: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/26603906/nvp-tae684-reverses-multidrug-resistance-mdr-in-human-osteosarcoma-by-inhibiting-p-glycoprotein-pgp1-function
#5
Shunan Ye, Jianming Zhang, Jacson Shen, Yan Gao, Ying Li, Edwin Choy, Gregory Cote, David Harmon, Henry Mankin, Nathanael S Gray, Francis J Hornicek, Zhenfeng Duan
BACKGROUND AND PURPOSE: Increased expression of P-glycoprotein (PGP1) is one of the major causes of multidrug resistance (MDR) in cancer, including in osteosarcoma, which eventually leads to the failure of cancer chemotherapy. Thus, there is an urgent need to develop effective therapeutic strategies to override the expression and function of PGP1 to counter MDR in cancer patients. EXPERIMENTAL APPROACH: In an effort to search for new chemical entities targeting PGP1-associated MDR in osteosarcoma, we screened a 500+ compound library of known kinase inhibitors with established kinase selectivity profiles...
February 2016: British Journal of Pharmacology
https://www.readbyqxmd.com/read/26485709/enhanced-g2-m-arrest-caspase-related-apoptosis-and-reduced-e-cadherin-dependent-intercellular-adhesion-by-trabectedin-in-prostate-cancer-stem-cells
#6
Eda Acikgoz, Ummu Guven, Fahriye Duzagac, Ruchan Uslu, Mikail Kara, Burak Cem Soner, Gulperi Oktem
Trabectedin (Yondelis, ET-743) is a marine-derived tetrahydroisoquinoline alkaloid. It is originally derived from the Caribbean marine tunicate Ecteinascidia turbinata and currently produced synthetically. Trabectedin is active against a variety of tumor cell lines growing in culture. The present study focused on the effect of trabectedin in cell proliferation, cell cycle progression, apoptosis and spheroid formation in prostate cancer stem cells (CSCs). Cluster of differentiation (CD) 133+high/CD44+high prostate CSCs were isolated from the DU145 and PC-3 human prostate cancer cell line through flow cytometry...
2015: PloS One
https://www.readbyqxmd.com/read/26456466/biosynthesis-of-tetrahydroisoquinoline-antibiotics
#7
Gong-Li Tang, Man-Cheng Tang, Li-Qiang Song, Yue Zhang
The tetrahydroisoquinoline (THIQ) alkaloids are naturally occurring antibiotics isolated from a variety of microorganisms and marine invertebrates. This family of natural products exhibit broad spectrum antimicrobial and strong antitumor activities, and the potency of clinical application has been validated by the marketing of ecteinascidin 743 (ET-743) as anticancer drug. In the past 20 years, the biosynthetic gene cluster of six THIQ antibiotics has been characterized including saframycin Mx1 from Myxococcus xanthus, safracin-B from Pseudomonas fluorescens, saframycin A, naphthyridinomycin, and quinocarcin from Streptomyces, as well as ET-743 from Ecteinascidia turbinata...
2016: Current Topics in Medicinal Chemistry
https://www.readbyqxmd.com/read/26219551/combined-trabectedin-and-anti-pd1-antibody-produces-a-synergistic-antitumor-effect-in-a-murine-model-of-ovarian-cancer
#8
Zhiqiang Guo, Haolin Wang, Fandong Meng, Jie Li, Shulan Zhang
BACKGROUND: Monoclonal antibodies (mAb) that block programmed death (PD)-1 signaling pathway hold great potential as a novel cancer immunotherapy. Recent evidence suggests that combining with conventional, targeted or other immunotherapies, these mAb can induce synergistic antitumor responses. In this study, we investigated whether Trabectedin (ET-743), a novel anticancer agent currently used for treating relapsed ovarian cancer, can synergize with anti (α)-PD-1 mAb to increase antitumor activity in the murine ID8 ovarian cancer model...
July 29, 2015: Journal of Translational Medicine
https://www.readbyqxmd.com/read/26013440/identification-and-analysis-of-the-bacterial-endosymbiont-specialized-for-production-of-the-chemotherapeutic-natural-product-et-743
#9
Michael M Schofield, Sunit Jain, Daphne Porat, Gregory J Dick, David H Sherman
Ecteinascidin 743 (ET-743, Yondelis) is a clinically approved chemotherapeutic natural product isolated from the Caribbean mangrove tunicate Ecteinascidia turbinata. Researchers have long suspected that a microorganism may be the true producer of the anticancer drug, but its genome has remained elusive due to our inability to culture the bacterium in the laboratory using standard techniques. Here, we sequenced and assembled the complete genome of the ET-743 producer, Candidatus Endoecteinascidia frumentensis, directly from metagenomic DNA isolated from the tunicate...
October 2015: Environmental Microbiology
https://www.readbyqxmd.com/read/25609059/trabectedin-efficacy-in-ewing-sarcoma-is-greatly-increased-by-combination-with-anti-igf-signaling-agents
#10
Ana Teresa Amaral, Cecilia Garofalo, Roberta Frapolli, Maria Cristina Manara, Caterina Mancarella, Sarah Uboldi, Silvana Di Giandomenico, Jose Luis Ordóñez, Victoria Sevillano, Roberta Malaguarnera, Piero Picci, A Bass Hassan, Enrique De Alava, Maurizio D'Incalci, Katia Scotlandi
PURPOSE: Goal of this study was to identify mechanisms that limit efficacy of trabectedin (ET-743, Yondelis) in Ewing sarcoma (EWS), so as to develop a clinical applicable combination therapy. EXPERIMENTAL DESIGN: By chromatin immunoprecipitation, we analyzed EWS-FLI1 binding to the promoters of several target genes, such as TGFβR2, CD99, insulin-like growth factor receptor 1 (IGF1R), and IGF1, both in vitro and in xenografts treated with trabectedin or doxorubicin...
March 15, 2015: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/25479910/anti-cancer-effect-and-gene-modulation-of-et-743-in-human-biliary-tract-carcinoma-preclinical-models
#11
Caterina Peraldo-Neia, Giuliana Cavalloni, Marco Soster, Loretta Gammaitoni, Serena Marchiò, Francesco Sassi, Livio Trusolino, Andrea Bertotti, Enzo Medico, Lorenzo Capussotti, Massimo Aglietta, Francesco Leone
BACKGROUND: Standard chemotherapy in unresectable biliary tract carcinoma (BTC) patients is based on gemcitabine combined with platinum derivatives. However, primary or acquired resistance is inevitable and no second-line chemotherapy is demonstrated to be effective. Thus, there is an urgent need to identify new alternative (chemo)therapy approaches. METHODS: We evaluated the mechanism of action of ET-743 in preclinical models of BTC. Six BTC cell lines (TFK-1, EGI-1, TGBC1, WITT, KMCH, HuH28), two primary cell cultures derived from BTC patients, the EGI-1 and a new established BTC patient-derived xenografts, were used as preclinical models to investigate the anti-tumor activity of ET-743 in vitro and in vivo...
December 5, 2014: BMC Cancer
https://www.readbyqxmd.com/read/25273374/ecteinascidins-a-review-of-the-chemistry-biology-and-clinical-utility-of-potent-tetrahydroisoquinoline-antitumor-antibiotics
#12
REVIEW
V H Le, M Inai, R M Williams, T Kan
The ecteinascidin family comprises a number of biologically active compounds, containing two to three tetrahydroisoquinoline subunits. Although isolated from marine tunicates, these compounds share a common pentacyclic core with several antimicrobial compounds found in terrestrial bacteria. Among the tetrahydroisoquinoline natural products, ecteinascidin 743 (Et-743) stands out as the most potent antitumor antibiotics that it is recently approved for treatment of a number of soft tissue sarcomas. In this article, we will review the backgrounds, the mechanism of action, the biosynthesis, and the synthetic studies of Et-743...
February 2015: Natural Product Reports
https://www.readbyqxmd.com/read/25050069/clinical-utility-of-trabectedin-for-the-treatment-of-ovarian-cancer-current-evidence
#13
REVIEW
Floriana Mascilini, Giulia Amadio, Maria Grazia Di Stefano, Manuela Ludovisi, Alessia Di Legge, Carmine Conte, Rosa De Vincenzo, Caterina Ricci, Valeria Masciullo, Vanda Salutari, Giovanni Scambia, Gabriella Ferrandina
Among the pharmaceutical options available for treatment of ovarian cancer, attention has been increasingly focused on trabectedin (ET-743), a drug which displays a unique mechanism of action and has been shown to be active in several human malignancies. Currently, single agent trabectedin is approved for treatment of patients with advanced soft tissue sarcoma after failure of anthracyclines and ifosfamide, and in association with pegylated liposomal doxorubicin for treatment of patients with relapsed partially platinum-sensitive ovarian cancer...
2014: OncoTargets and Therapy
https://www.readbyqxmd.com/read/24941346/anti-angiogenic-effects-of-trabectedin-yondelis-et-743-on-human-breast-cancer-cells
#14
Harika Atmaca, Selim Uzunoglu
Trabectedin, a tetrahydroisoquinoline alkaloid derived from a Caribbean tunicate Ecteinascidia turbinata, has been shown to have antitumor effects. In this study, we assessed the possible anti-angiogenic effects of trabectedin on human umbilical vein endothelial cells (HUVECs) and breast cancer cell lines. An XTT cell viability assay was used to determine cytotoxicity. A scratch assay was used to detect the migration of cells after trabectedin treatment. Angiogenic cytokine profiles of breast cancer cell lines, before and after treatment with trabectedin, were investigated using an angiogenesis antibody array...
March 1, 2014: European Cytokine Network
https://www.readbyqxmd.com/read/23792433/a-diverse-induction-of-apoptosis-by-trabectedin-in-mcf-7-her2-er-and-mda-mb-453-her2-er-breast-cancer-cells
#15
Harika Atmaca, Emir Bozkurt, Selim Uzunoglu, Ruchan Uslu, Burcak Karaca
Trabectedin (Yondelis, ET-743), a semi synthetic tetrahydroisoquinoline alkaloid that was originally derived from the marine tunicate Ecteinascidia turbinata. The objective of this study was to investigate whether trabectedin mediated apoptosis shows any diversity in human breast cancer cell lines with different genotypes. Trabectedin induced cytotoxicity and apoptosis in both breast cancer cells in a time and concentration-dependent manner. The expression levels of the death receptor pathway molecules, TRAIL-R1/DR4, TRAIL-R2/DR5, FAS/TNFRSF6, TNF RI/TNFRSF1A, and FADD were significantly increased by 2...
August 14, 2013: Toxicology Letters
https://www.readbyqxmd.com/read/23774301/trabectedin-as-single-agent-in-the-salvage-treatment-of-heavily-treated-ovarian-cancer-patients-a-retrospective-multicenter-study
#16
MULTICENTER STUDY
Gabriella Ferrandina, Vanda Salutari, Bruno Vincenzi, Marco Marinaccio, Emanuele Naglieri, Vera Loizzi, Silvia Carpano, Giulia Amadio, Giuseppe Tonini, Giovanni Scambia, Domenica Lorusso
OBJECTIVE: The aim of this multicenter, retrospective study was to evaluate the efficacy and the safety of single agent Trabectedin (ET-743, Yondelis) in very heavily treated, relapsed ovarian cancer (ROC) patients. PATIENTS AND METHODS: Response to treatment was classified according to RECIST criteria. Progression-free (PFS), and overall survival (OS) were also assessed. RESULTS: 98 patients were analyzed (originally 67 platinum sensitive, and 31 platinum refractory/resistant)...
September 2013: Gynecologic Oncology
https://www.readbyqxmd.com/read/23149213/the-impairment-of-the-high-mobility-group-a-hmga-protein-function-contributes-to-the-anticancer-activity-of-trabectedin
#17
Daniela D'Angelo, Eleonora Borbone, Dario Palmieri, Sarah Uboldi, Francesco Esposito, Roberta Frapolli, Roberto Pacelli, Maurizio D'Incalci, Alfredo Fusco
Trabectedin (Ecteinascidin-743 or ET-743) is a novel antitumour agent of marine origin with potent antitumour activity both in vitro and in vivo. It interacts with the minor groove of DNA, interfering with transcriptional activity and DNA repair pathways. Here, we report a novel mechanism by which trabectedin exerts its cytotoxic effects on carcinoma cells. It is based on its ability to impair the function of the High-Mobility Group A (HMGA) proteins. These proteins have a key role in cell transformation, and their overexpression is a common feature of human malignant neoplasias, representing a poor prognostic index often correlated to anti-cancer drug resistance...
March 2013: European Journal of Cancer
https://www.readbyqxmd.com/read/23085431/prospects-and-challenges-for-the-development-of-new-therapies-for-ewing-sarcoma
#18
REVIEW
Patrick J Grohar, Lee J Helman
The Ewing sarcoma family of tumors or Ewing sarcoma (ES) is the second most common malignant bone tumor of childhood. The prognosis for localized Ewing sarcoma has improved through the development of intense multimodal therapy over the past several decades. Unfortunately, patients with recurrent or metastatic disease continue to have a poor prognosis. Therefore, a number of complementary approaches are being developed in both the preclinical and clinical arenas to improve these outcomes. In this review, we will discuss efforts to directly target the biologic drivers of this disease and relate these efforts to the experience with several different agents both in the clinic and under development...
February 2013: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/22847981/a-phase-i-trial-and-pharmacokinetic-study-of-a-24-hour-infusion-of-trabectedin-yondelis%C3%A2-et-743-in-children-and-adolescents-with-relapsed-or-refractory-solid-tumors
#19
Meredith K Chuk, Alberta Aikin, Trish Whitcomb, Brigitte C Widemann, Peter Zannikos, Eliel Bayever, Frank M Balis, Elizabeth Fox
BACKGROUND: The objectives of this phase I study were to determine the maximum tolerated dose (MTD), toxicity profile, and pharmacokinetics of a 24-hour continuous intravenous infusion of trabectedin administered to children and adolescents with refractory or relapsed solid tumors. PROCEDURE: Patients between the ages of 4 and 16 years old with refractory solid tumors received trabectedin as a 24-hour infusion every 21 days. Dexamethasone and prophylactic growth factor support were administered with each cycle...
November 2012: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/22591421/trabectedin-as-a-new-chemotherapy-option-in-the-treatment-of-relapsed-platinum-sensitive-ovarian-cancer
#20
REVIEW
Bradley J Monk, Heather Dalton, Ivor Benjamin, Adnan Tanović
Trabectedin (ET-743, Yondelis®) is a novel marine antineoplastic alkaloid with a unique mechanism of action. The active substance trabectedin, a tetrahydroisoquinoline alkaloid, is a natural product originally isolated from the Caribbean sea squirt, Ecteinascidia turbinata and is currently manufactured by total synthesis. Trabectedin is licensed by the Spanish pharmaceutical drug company, PharmaMar and co-developed by Johnson & Johnson Pharmaceutical Research and Development, L.L.C., pursuant to a licensing agreement with PharmaMar...
2012: Current Pharmaceutical Design
keyword
keyword
119421
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"